inno.N

Achievements

Based on the differentiated research capabilities and experience in developing a wide range of products,
inno.N continues its R&D for next-generation pharmaceutical products.

R&D results

Based on the differentiated research capabilities and experience in developing a wide range of products, inno.N continues its R&D for next-generation pharmaceutical products.

K-CAB
The 30th novel drug to be developed and registered in Korea; Currently holds the largest share in the market for anti-ulcer drugs.
  • Launched as a treatment for GERD in 2019
  • Addressed the shortcomings of PPI and H2RA treatments.
  • Excellent efficacy compared to competing P-CAB products.
  • Over 100 billion won worth of products have been prescribed within the shortest span in time of all novel drugs in Korea.
    1. 2021
    2. 2020
    3. 2019
    4. 2018
    5.  
    6. 2017
    1. Technologies applied to manufacturing K-CAB are exported to U.S.A. and Canada

    2. “K-CAB” received USFDA approval for Phase 1 clinical trials.

    3. K-CAB, the 30th novel drug to be developed and registered in Korea, is launched in tablet form.

    4. K-CAB (with Tegoprazan as the active ingredient) receive approval from the Korean Ministry of Food & Drug Safety to be used as a drug for GERD.
      Korea’s 30th novel drug

    5. Technologies for CJ-40001 (second generation EPO) are exported to the China-based company, NCPC Genetech Biotechnology.

    6. Technologies for CJ-40001 (second generation EPO) are exported to the Japan-based company, YL Biologics.

    1. 2016
    2.  
    3. 2014
    4.  
    5. 2013
    6. 2012
    1. Machkhan, an improved and modified drug for hypertension, is launched
      A drug with the combined active ingredients of ARB(angiotensin II receptor blocker) and CCB(calcium-channel blocker)
      The first drug to combine the active ingredients of Candesartan /Amlodipine

    2. K-CAB, a novel drug developed in-house to treat GERD is approved by the Korean Ministry of Food and Drug Safety
      A novel drug in the category of P-CAB drugs (potassium competitive acid blockers).
      Related technologies are exported to Luoxin, China (2015)
      Application is filed for approval as a novel drug (2017)

    3. Vogmet, an improved and modified drug to treat diabetes, is launched.
      A drug with the combined active ingredients of α-glucosidase and biguanides
      The first drug to combine the active ingredients of voglibose and metformin.

    4. Tegoprazan,
      Selected by the government as a key initiative for the development of novel drugs in all phases

    5. Exone, a combined drug treatment for hypertension, is launched.
      A drug with the combined active ingredients of ARB(angiotensin II receptor blocker) and CCB(calcium-channel blocker)
      A drug with the combined active ingredients of Valsartan and
      Outstanding photo-stability due to differentiated technologies

    6. inno.N is selected by the Ministry of Health and Welfare as an ‘innovative pharmaceutical firm’.
      inno.N is recognized for its outstanding R&D for novel drugs and export capabilities.

    1. 1998
    2. 1995
    3. 1992
    4. 1986
    1. Epokine, a treatment for anemia, is launched.
      inno.N becomes the first company in Korea and the third company in the world to develop an EPO drug.

    2. Citopcin injection acquires certification for ‘domestic new technologies’ and is given the Chang Young Sil Award.
      The first drug in Korea to use TOF, a biological substance

    3. Anti-hangover beverage Condition is launched.
      Condition becomes the first anti-hangover beverage to be introduced in the Korean market

    4. Hepaccine-B, a vaccine for Hepatitis B, is launched.
      Hepaccine-B is the first vaccine for Hepatitis B to be developed in Korea and the second to be developed in the world.
      Certification from the WHO (1993)

TOP